Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
The combined company will be able to better serve both our global and regional customers with local production
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company is investing more than €100 million in the expansion of the Halle site
Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.
The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at Indore plant.
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Krsnaa Diagnostics now has its footprints in Delhi.
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
VACUUBRAND has evolved rapidly in recent years, developing new innovative vacuum technology for laboratories, research and engineering
The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
